{
  "ticker": "BDTX",
  "company_name": "Black Diamond Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04209465",
      "title": "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Solid Tumor",
      "start_date": "2019-12-19",
      "completion_date": "2022-09-16",
      "enrollment": 0,
      "sponsor": "Black Diamond Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07326566",
      "title": "Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE2",
      "condition": "Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer",
      "start_date": "2026-04",
      "completion_date": "2029-03",
      "enrollment": 0,
      "sponsor": "Black Diamond Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05256290",
      "title": "Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation",
      "start_date": "2022-03-31",
      "completion_date": "2026-06",
      "enrollment": 0,
      "sponsor": "Black Diamond Therapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 3,
    "by_phase": {
      "PHASE1": 1,
      "PHASE2": 1,
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "TERMINATED": 1,
      "NOT_YET_RECRUITING": 1,
      "ACTIVE_NOT_RECRUITING": 1
    },
    "active_trials": 1,
    "completed_trials": 0,
    "conditions": [
      "Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer",
      "Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation",
      "Solid Tumor"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:43:49.583050",
    "search_query": "Black Diamond Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Black+Diamond+Therapeutics,+Inc."
  }
}